A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Daratumumab (Primary) ; Atezolizumab
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CALLISTO
- Sponsors Janssen Research & Development
- 20 Jul 2017 Planned End Date changed from 30 Nov 2018 to 4 Jan 2019.
- 23 Jun 2017 Planned End Date changed from 25 Jan 2019 to 30 Nov 2018.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology